

TERMS OF REFERENCE

RISK COMMITTEE

REVIEWED BY THE COMMITTEE ON 5 OCTOBER 2020

APPROVED BY THE BOARD ON 23 NOVEMBER 2020

Table of content

1.	Introduction	3
2.	Purpose of these terms of reference	3
3.	Composition	3
4.	Mandate	4
5.	Reporting	5
6.	Authority.....	5
7.	Administration and meetings.....	5
8.	Approval of the terms of reference	6

1. Introduction

The risk committee (“**the Committee**”) is constituted as a standing committee of the board of directors (“**the Board**”) of Reunert Limited (“**the Company**”) and its subsidiaries, and affiliates to the extent relevant (“**the Reunert Group**”), to assist the Board to perform its oversight role in respect of risk management, and matters related thereto, as set out in these terms of reference.

2. Purpose of these terms of reference

The purpose of this document is to constitute the terms of reference for the Committee by setting out the role and responsibilities of the Committee, to regulate the affairs of the Committee and deal with administrative matters relating thereto.

3. Composition

3.1 Appointment of and requirements relating to members

The chair of the audit committee, the chief executive officer and the chief financial officer of the Company will be members of the Committee, *ex officio*.

The Committee must have at least five members. Three of its members must be independent non-executive directors. The collective skills and experience of the members must be appropriate to carrying out the role and associated responsibilities of the Committee.

Members of the Committee are recommended by the nomination and governance committee and appointed from time to time by the Board.

3.2 Filling of casual vacancies

The Board must appoint an individual to fill a vacancy (that is, when the number of members on the Committee falls below five), as soon as possible, but no later than six calendar months after the vacancy arose.

The Committee may continue to execute its mandate and will be able to take binding decisions on matters that fall within its mandate (including in circumstances where the Board fails to fill a vacancy as envisaged above), if it has less than five, but not less than three, members.

3.3 Attendance by request

The Committee may require any employee of the Reunert Group, external consultant, or subject matter expert, to attend some or all of the meetings of the Committee, but (unless appointed to the Committee in accordance with the process in paragraphs 3.1 and 3.2) these individuals may not be members of the Committee and, as such, may not vote on any matters before the Committee.

3.4 Chair

The nomination and governance committee recommends, for approval by the Board, a member of the Committee to be its chair. The chair must be an independent non-executive director of the Company.

If the appointed chair of the Committee is absent from a meeting, the members present shall elect one of them to act as chair of that meeting.

4. Mandate

The role and associated responsibilities and functions of the Committee are to:

4.1 Risk governance

- oversee the development of and annually review a framework and plan for risk management in accordance with the principles of the King IV Code on Corporate Governance , with the aim to enhance the Reunert Group’s ability to achieve its strategic objectives;
- monitor that the enterprise risk management framework and methodologies are implemented throughout the Reunert Group;
- oversee the process whereby risks are identified and managed;
- oversee the development of and annually review the Group’s risk tolerance (being the limit of potential loss that Reunert has the capacity to tolerate) and risk appetite (being the Reunert Group’s propensity to take appropriate levels of risk) framework. In this regard:
 - to monitor that risks are managed within the levels of appetite and tolerance;
 - to ensure that risks are prioritised and addressed accordingly;
- oversee that the potential negative impact of risk is appropriately mitigated;
- consider and review management’s and internal audit’s reports on:
 - the appropriateness of the Reunert Group’s risk framework and risk appetite and tolerance levels;
 - the adequacy and overall effectiveness of the Reunert Group’s enterprise risk management framework and the integration of risk management into the day-to-day activities of the Reunert Group; and
 - internal control, confirming that appropriate action has been taken as required and appropriate risk responses were considered and implemented;
- ensure that Reunert’s strategy and business plans take account of the material risks that the Reunert Group is or may be exposed to; and
- consider the risk environment from time to time, as deemed appropriate and based on materiality and changes in the external, transactional and internal environments.

4.2 Specific matters to be overseen by the Committee

- ensure that management implements appropriate business continuity arrangements;
- review the annual renewal process relating to insurance arrangements in the Reunert Group;
- obtain assurance from management in respect of the adequacy and effectiveness of internal controls;
- support the appropriate interaction between the Group’s risk management processes and its assurance processes and interact with the Company’s audit committee, as appropriate, on matters that are relevant to the mandate of the audit committee; and
- consider and advise the Board on the need to receive independent assurance on the design and operational effectiveness of risk management.

4.3 Disclosures and risk specific reporting

- monitor whether disclosures regarding risk are comprehensive, timely and relevant;
- express the Committee’s formal opinion to the Board on the effectiveness of risk management; and
- oversee reporting to stakeholders on organisational risks and opportunities (but without compromising sensitive information), in accordance with paragraphs 8.63 and 7.F.7 of the JSE Listings Requirements¹, as well as:

¹ Paragraph 7.F.7 provides as follows: “A description of all material risks which are specific to the issuer, its industry and/or its securities. Proper consideration must be given to the material risks that face the

- the nature and extent of the risks and opportunities that Reunert is willing to take;
- the arrangements for governing and managing risk; and
- actions taken to monitor the effectiveness of risk management and how the outcomes were addressed.

4.4 Other delegated duties

The Board may, by way of its formal “Delegation of Authority” document, or on an ad hoc basis, mandate the Committee to fulfil any additional functions that the Board may deem appropriate.

5. Reporting

With respect to its activities during each financial year the Committee discloses by way of the integrated report or another publicly available platform (as the Committee in its discretion decides), on matters which fall within its mandate and as recommended by the King IV Code:

- its overall role and associated responsibilities and functions;
- its composition, including each members’ qualifications and experience;
- any external advisors or invitees who regularly attend meetings;
- key areas of focus during the reporting period and key areas of future focus;
- the number of meetings held during the reporting period and attendance at those meetings; and
- whether the Committee is satisfied that it has fulfilled its responsibilities in accordance with these terms of reference, for the reporting period.

6. Authority

The Committee has the authority to:

- investigate, monitor and report to the Board on any activity within the scope of its mandate as contemplated in these terms of reference, the formal “Delegation of Authority Document”, or granted on an ad hoc basis, and to take and implement decisions on such matters to the extent that the authority to do so is expressly or impliedly bestowed in terms of its mandate;
- sub-delegate any of the authority delegated to it;
- in the fulfilment of its roles and associated responsibilities, call on the chairs of other Board committees, any of the executive directors or officers, or the company secretary of the Company to provide it with information, subject to following a Board-approved process;
- access the records of the Company and its subsidiaries, facilities and any other resources necessary to discharge its role and associated responsibilities, subject to following a Board-approved process; and
- obtain independent outside professional advice to assist with the execution of its role and associated responsibilities, at the cost of the Company, subject to following a Board-approved process.

7. Administration and meetings

7.1 Frequency

The Committee must hold a minimum of two meetings in any financial year.

Meetings in addition to those scheduled before the commencement of each calendar year, may be scheduled by the chair of the Committee, in consultation with the secretary, or at the instance of the Board.

applicant issuer and generic disclosures must be avoided. Material risks should be grouped together in a coherent manner and material risks considered to be of the most immediate significance should be prominent at the beginning within the material risks disclosure.

The nomination and governance committee must be advised of a proposed permanent change to the frequency or timing of meetings of the committee.

7.2 Attendance

Committee members are expected to make every effort to attend all meetings of the Committee, including meetings called on an ad hoc-basis.

If it is not possible for a member of the Committee to attend any meeting of the Committee, prior apology, with reasons, shall be submitted to the chair of the Committee or to its secretary.

7.3 Quorum

The Committee shall not have a quorum to proceed with a meeting if more than one of its members are not present.

Invitees and the secretary are not taken into account when determining a quorum.

8. Approval of the terms of reference

These terms of reference were recommended to the Board by the Committee following review by its members on **5 October 2020** and approved by the Board on **23 November 2020**.